BridgeBio Pharma Inc

Common Name

BridgeBio Pharma

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

725

Ticker

BBIO

Exchange

NASDAQ/NGS

Website

bridgebio.com

Description

BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purp... Show more

Financial Statements of BridgeBio Pharma

Below are the financial statements of BridgeBio Pharma, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in millions of USD	2024	2023	2022
Revenue, net	221.9^a	9.3^a	77.65^a
Operating costs and expenses	—	—	—
Cost of revenue	-3.88^a	-2.45^a	-3.43^a
Research and development	-506.46^a	-455.71^a	-399.46^a
Selling, general and administrative	-288.93^a	-150.59^a	-143.19^a
Restructuring, impairment and related charges	-15.61^a	-7.93^a	-43.77^a
Total operating costs and expenses	-814.88^a	-616.67^a	-589.85^a
Loss from operations	-592.97^a	-607.37^a	-512.2^a
Other income (expense), net	—	—	—
Interest income	17.25^a	18.04^a	7.54^a
Interest expense, net	-99.29^a	-81.29^a	-80.44^a
Gain on deconsolidation of subsidiaries	178.32^a	0^a	0^a
Loss on extinguishment of debt	-26.59^a	0^a	0^a
Net loss from equity method investments	-31.18^a	0^a	0^a
Gain from sale of priority review voucher, net	0^a	0^a	107.95^a
Other income (expense), net	12.27^a	17.37^a	-7.5^a
Total other income (expense), net	50.78^a	-45.88^a	27.55^a
Loss before income taxes	-542.19^a	-653.25^a	-484.65^a
Income tax expense	-1.15^a	0^a	0^a
Net loss	-543.35^a	-653.25^a	-484.65^a
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests	7.59^a	10.05^a	3.47^a
Net loss attributable to common stockholders of BridgeBio	-535.76^a	-643.2^a	-481.18^a

Verified Sources Behind BridgeBio Pharma’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore BridgeBio Pharma’s data sources below and access millions more through our Disclosure Search.

a. BridgeBio Pharma's 10-K 2024

Trace every data point back to BridgeBio Pharma’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

BridgeBio Pharma Inc

Financial Statements of BridgeBio Pharma

Verified Sources Behind BridgeBio Pharma’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

TG Therapeutics Inc

Vericel Corp

Blueprint Medicines Corp

ADMA Biologics Inc

Ultragenyx Pharmaceutical Inc

Axsome Therapeutics Inc